Key Takeaways
- A tumour board is a treatment-planning meeting in which cancer clinicians and other specialists review selected cases together.[1] It is not simply several appointments placed on the same itinerary.
- The useful output is a patient-specific record: question, evidence reviewed, participants, options, recommendation, uncertainty and next owner.
- The patient may not attend the meeting. A named clinician must explain the recommendation, alternatives and trade-offs afterward and invite the patient’s preferences into the final decision.[4][5]
- “Consensus” does not mean certainty. A team may agree on a conditional plan, request more evidence or document more than one reasonable option.
- MDT discussion can improve coordination, but the label itself does not guarantee correct staging, timely care or better outcomes. Check the inputs and whether the plan was implemented.
Content
Cancer care becomes multidisciplinary because no single specialty owns all of the evidence. The pathologist defines the tumour, the radiologist maps its extent, surgeons judge resectability, medical and radiation oncologists compare treatment sequences, and nursing, pharmacy, rehabilitation, genetics, nutrition or palliative-care professionals may identify risks that change what is realistic.
The meeting is valuable only when those perspectives converge on one explicit clinical question. A room full of experts looking at an incomplete file can still produce an incomplete recommendation.
Distinguish Three Services That May Be Called “MDT”
Tumour board meeting
Specialists meet—often without the patient—to review evidence and agree or record options. NCI defines tumour board review as a regular treatment-planning process involving cancer doctors and other health professionals for new or complex cases.[1]
Multidisciplinary clinic
The patient attends a coordinated service and may meet several professionals on the same day. The team can share information, but the visit structure varies; ask whether there is a formal case conference and written outcome.
Multiple specialist opinions
Several doctors review the case separately. This can be helpful, but it is not a tumour board unless the opinions are reconciled into a joint record.
Ask which format the hospital is offering, whether the patient joins any portion, and who is responsible for the final conversation.
Start With One Decision Question
A tumour board should not be asked to “review everything.” Frame the decision, for example:
- Is the tumour resectable now, or should systemic therapy come first?
- Does the pathology support the diagnosis assumed in the current plan?
- Is local treatment appropriate for limited metastatic disease?
- Which treatment intent—curative, disease-controlling or symptom-focused—is realistic?
- Is a new biopsy needed before choosing a targeted or immune therapy?
- How should frailty, organ function, fertility or a competing illness change the plan?
China’s National Health Commission has encouraged single-disease, multidisciplinary care for complex cancer cases, naming oncology, surgery, radiotherapy, pathology, pharmacy, imaging, laboratory medicine and nuclear medicine among relevant disciplines.[2]
The required members should follow the question, not a fixed photo of “five experts.” A sarcoma discussion may need a specialist pathologist and musculoskeletal radiologist; a liver tumour discussion may need hepatobiliary surgery and interventional radiology; a frail patient may need geriatrics and supportive care.
Make Sure the Case Is Ready for Discussion
The coordinator should circulate a structured case packet before the meeting:
- confirmed or working diagnosis and tumour type;
- pathology report and whether source slides were reviewed;
- current stage and the evidence used for it;
- relevant DICOM imaging, not screenshots alone;
- prior treatments, responses and toxicities;
- performance status, organ function and major comorbidities;
- medicines, allergies and infection or bleeding risks;
- patient goals, constraints and decisions already declined;
- exact question and deadline.
NCI notes that tumour review boards consider pathology together with other tests when planning treatment.[6] If imaging or pathology is unavailable, the outcome should state that limitation rather than imply a complete review.
Verify Who Was Present—and Who Was Missing
Request the participants by specialty and role. Names may be useful, but functions matter more:
Role · Question contributed
Pathology · What is the tumour, and how certain is the classification?
Radiology / nuclear medicine · Where is disease present, and what remains uncertain?
Surgery · Is an operation technically and medically feasible?
Medical oncology · What systemic options fit this disease and patient?
Radiation oncology · Is radiation indicated, deliverable and how should it be sequenced?
Nursing / pharmacy · Can the plan be delivered safely and understood?
Rehabilitation / nutrition / palliative care · What function, symptom or support risks require action?
If a key specialty is absent, ask whether its opinion was submitted in advance or whether the case must return for another meeting.
Read the Recommendation as a Conditional Statement
A strong MDT outcome might say:
If pathology review confirms X and repeat imaging shows no Y, the team recommends A followed by B. If either condition fails, option C should be reconsidered.
This is more useful than “MDT recommends surgery.” It exposes the assumptions and the branch points.
The record should include:
- decision question;
- evidence reviewed and dates;
- working diagnosis and stage;
- treatment intent;
- options considered, including no immediate treatment when relevant;
- reasons for the preferred option;
- material risks or disadvantages;
- dissent or unresolved uncertainty;
- tests needed before commitment;
- responsible clinician and review date.
NHS England’s MDT guidance focuses full meeting time on patients with complex needs.[4] A streamlined pathway can be reasonable for routine cases, provided protocols, exceptions and accountability are clear. “Not discussed live” should not mean “no one made a documented decision.”
Separate Team Advice From Patient Consent
The tumour board advises; the patient decides after an appropriate clinical discussion. A recommendation developed without the patient in the room may not yet account for fertility, work, caregiving, religious values, tolerance for risk or a strong preference to avoid a particular outcome.
NICE’s shared-decision framework emphasises that individual needs, preferences and values must be considered alongside evidence, especially where options involve trade-offs.[5]
After the meeting, ask the responsible clinician to explain:
- What is the team trying to achieve?
- Which alternatives were reasonable?
- What benefit is expected, and how uncertain is it?
- What harms, burdens and irreversible consequences matter?
- What happens if the patient waits or declines?
- Which part of the recommendation changes with the patient’s priorities?
The phrase “the MDT decided” should never be used to end this conversation.
Plan an International Case Before Travel
Ask whether the hospital can review the case remotely and what must be translated. Provide original reports alongside translations and identify which imaging and pathology files have actually been imported.
Clarify the service boundary:
- Is the fee for file screening, formal tumour board review or a patient-facing consultation?
- Will a signed report be issued?
- Can the patient submit questions?
- Does the recommendation reserve an appointment or bed?
- What changes after physical examination in China?
- Who answers the home oncologist?
A board recommendation may be sufficient to avoid unnecessary travel, or it may identify one missing biopsy that should be done first. Do not treat attendance in China as proof that the team has already accepted the proposed treatment.
Know When the Case Should Return to the Board
Re-discussion may be needed when:
- pathology or stage changes;
- a required biomarker returns;
- the patient does not respond as expected;
- treatment causes toxicity that alters the risk–benefit balance;
- surgery reveals different findings;
- the patient’s health or goals change;
- a clinical trial or new option becomes relevant;
- the team’s conditional assumptions are no longer true.
The initial report should name these triggers. Otherwise “MDT follow-up” can become a vague promise with no owner.
Audit the Plan, Not Just the Meeting
The National Health Commission’s tumour-MDT pilot aimed to improve standardised diagnosis and treatment and patient safety.[3] Those goals depend on execution after the meeting.
For each action, record:
Action · Owner · Due date · Completion evidence
Pathology review · Final report
Additional imaging · Images and signed interpretation
Patient decision visit · Consent or documented choice
Treatment booking · Date and service line
Supportive-care referral · Appointment or plan
Home-team handover · Sent and acknowledged
A recommendation that never reaches the patient or cannot be implemented is not coordinated care.
Questions to Ask About an MDT Service
- What cases does this tumour board cover?
- Which core specialties attend, and how often?
- Will my pathology and imaging be formally reviewed?
- What clinical question will be presented?
- Will the written outcome show uncertainty and alternatives?
- Who explains it to me in my language?
- Can my home oncologist receive or discuss the report?
- What triggers re-discussion?
- Is the fee separate from consultations and tests?
- Who tracks whether actions actually happen?
Medical disclaimer: Tumour-board review is a planning process, not a diagnosis, guarantee or substitute for informed consent. The treating clinician must apply the recommendation to the patient’s current condition and preferences. Urgent deterioration requires immediate clinical assessment rather than waiting for a scheduled meeting.
Related Hospitals
Link a hospital only after verifying a disease-specific tumour board, its core membership, record requirements, written output and route for international patients. The original generic hospital list has been removed.
Related Treatments
An MDT may compare surgery, systemic therapy, radiotherapy, local procedures, clinical trials, surveillance and supportive care. Link only the options actually considered for the patient’s diagnosis and treatment intent.
Related Guides
- Pathology Review Before Cancer Treatment in China
- Getting a Cancer Second Opinion in China
- How to Share CT, MRI and Other Imaging Files With a Chinese Hospital
- How to Find a Clinical Trial in China
- How to Request an Itemized Treatment Cost Estimate
FAQ
Does the patient attend a tumour board meeting?
Often not. Tumour boards are usually clinician meetings, while multidisciplinary clinics may include the patient.[1] Ask which format is offered and who will explain the outcome.
Does an MDT recommendation mean the treatment is definitely correct?
No. It reflects the evidence and expertise available at that time. Missing material, new results or patient preferences can change the plan.
Must every specialist agree?
Not necessarily. The record should show unresolved issues or reasonable alternatives instead of presenting false unanimity.
Can an international case be discussed before travel?
Sometimes. The hospital must confirm that it accepts remote records and whether pathology and DICOM imaging can be formally reviewed. An administrative file check is not the same service.
When should a case return to the tumour board?
When a diagnosis, stage, biomarker, response, toxicity, surgical finding, health condition or patient goal changes enough to affect the recommendation.
Sources
- US National Cancer Institute — Definition of Tumor Board Review
- National Health Commission of China — Strengthening Standardised Cancer Diagnosis and Treatment
- National Health Commission of China — Cancer Multidisciplinary Diagnosis and Treatment Pilot
- NHS England — Streamlining Multidisciplinary Team Meetings: Guidance for Cancer Alliances
- NICE — Shared decision-making principles for patient decision aids
- US National Cancer Institute — Surgical Pathology Reports and Tumor Review Boards
Hero Image Review
- Decision: Rejected; replacement pending as hero-reviewed.png.
- Why: The original shows one doctor presenting to a patient and companion. A small “group” icon is not enough to represent specialists jointly reviewing imaging, pathology and treatment options.
- Replacement brief: A genuine conference scene with a surgeon, medical oncologist, radiation oncologist, radiologist and pathologist around one non-readable case display; balanced participation, no logos, patient identifiers or futuristic holograms.